Drug Detail

Information about Votrient

Generic Name
Brand Name (US)
Drug Type
Tyrosine Kinase Inhibitor
Approval Status
Approved for a non-GIST cancer
Renal cell carcinoma (RCC) and Soft-tissue Sarcoma (but not GIST) in the U.S.
Overall Strategy
KIT Protein Based
Block KIT + Block blood vessel growth
Drug Category
KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI)

Pazopanib is a multi-tyrosine kinase inhbitor that inhibits the VEGF receptors (1,2 & 3) as well as KIT and PDGFRA and PDGFRB. In this respect it is similar to Sutent and Nexavar. At higher concentrations, it appears to inhibit Aurora A kinase. It is unknown whether it inhibits Aurora A at clinically achievable concentrations.
On October 19, 2009, pazopanib was approved in the US for renal cell carcinoma (kidney cancer). In 2012, it was approved for soft-tissue sarcoma. It is not approved for GIST. Pazopanib is in phase 2 trials for GIST (2012).
Severe liver toxicity has been noted in some patients and regular monitoring of liver function is important. Drug-related deaths were observed in 2.2% of 593 patients and included hepatic failure (n=2), hemorrhage (n=6),arterial thrombotic events (n=3) and perforation (n=2). See link below about changes to liver monitoring frequency.
In RCC patients, the recommended dose of pazopanib is 800 mg orally once daily without food (at least1 hour before or 2 hours after a meal). The dose of pazopanib should not exceed 800 mg. Do not crush tablets due to the potential for increased rate of absorption which may affect systemic exposure. The prescribing information (US), indicates a starting dose of 200 mg/day for patients with moderate liver impairment. Pazopanib is not recommended for patients with severe liver impairment.
If a dose is missed, it should not be taken if it is less than 12 hours until the next dose.



Votrient.com website


Highlights of prescribing info and full text of prescribing information (PDF)


Commitment to Access - GSK's patient assistance program for access to drugs


Votrient - Important changes to frequency of liver test monitoring (PDF)


Help for patients without drug coverage


FDA approves Votrient® for treatment of patients with certain types of advanced soft tissue sarcoma


Medical News TODAY article - FDA approves GSK's VOTRIENT (TM) for advanced renal cell cancer


Pazopanib IC50 Table


Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma (full text article, with good discussion of side effects)


Pazopanib-induced hyperbilirubinemia (liver problems) is associated with Gilbert's syndrome UGT1A1 polymorphism - Full text article


Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis


In the Pipeline: Positive Early Results with Pazopanib in Bladder Cancer


Votrient on rxlist.com


FDA presentation: Key new drug applicant information


FDA approves GSK's Votrient for advanced renal cell cancer (GSK website)


The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma


Suppression of the Nitric Oxide Pathway in Metastatic Renal Cell Carcinoma Patients Receiving Vascular Endothelial Growth Factor–Signaling Inhibitors (PDF)

Trials of this drug


Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)


Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST) (PAZOGIST)


Pazopanib in Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib (PAGIST)

Trial results

  A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib

Search for this drug/combination in: